Douglas Beall, M.D., chief of radiology services at Clinical Radiology of Oklahoma and principal investigator of the VAST study, will be presenting data from VIVEX’s 12-month study of VIA Disc® for ...
“For patients currently suffering from degenerative disc disease, the availability of therapeutic options is limited or sub-optimal,” said Dr. Davis. “I believe intradiscal allogeneic treatments like ...
Analysis of 1,804 Medicare beneficiaries per group demonstrates a meaningful shift in the continuum of care following intradiscal nucleus pulposus allograft procedure MIAMI, June 05, 2026 (GLOBE ...
Patients received a single injection of 100 mg of VIA Disc NP, a micronized cadaveric disc tissue product reconstituted with saline. Under fluoroscopic guidance, the product was delivered into ...
First-ever published 12-month results from Level 1 intradiscal study for treating patients with one or two level symptomatic degenerative disc disease Early evidence suggests greater than 70% ...
An injection that relieves low back pain by helping damaged spinal discs regenerate appears to have sustained benefits, new clinical trial data show. Most patients who received an injection of VIA ...
MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND ...
MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced the publication of a new real-world evidence study demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results